

Veracyte, NanoString agreement

January 2020—Veracyte and NanoString have entered into an agreement in which Veracyte has obtained exclusive worldwide rights to develop and commercialize diagnostic tests on NanoString's nCounter Flex system.

Veracyte plans to expand the portfolio of nCounter-based diagnostic products with its Envisia classifier, for use in idiopathic pulmonary fibrosis diagnosis, to international customers in 2021 and expects its in-development nasal swab classifier, for use in lung cancer diagnosis, to follow in 2022. Veracyte has also acquired the rights to the NanoString 510(k)-cleared Prosigna breast cancer assay and nCounter Dx LymphMark assay, which is currently available for research and investigational use only.

Veracyte will pay NanoString \$50 million in cash and Veracyte stock plus up to \$10 million in cash upon the commercial launch of Veracyte diagnostic tests for use on the nCounter platform.

[Veracyte](#), 650-243-6300

[NanoString](#), 888-358-6266